SuperworthGalectin Therapeutics shares outstanding GALT
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 65.9M
- On a year earlier
- +3.8%
- more shares
Galectin Therapeutics had 65.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 3.8% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 64.7M | +3% |
| FY2024 | 62.7M | +1% |
| FY2023 | 61.8M | +4% |
| FY2022 | 59.4M | +0% |
| FY2021 | 59.3M | +4% |
| FY2020 | 57.1M | +34% |
| FY2019 | 42.6M | +3% |
| FY2018 | 41.2M | +8% |
| FY2017 | 38.3M | +29% |
| FY2016 | 29.7M | +15% |
| FY2015 | 25.9M | +17% |
| FY2014 | 22.2M | +22% |
| FY2013 | 18.2M | +14% |
| FY2012 | 16M | +24% |
| FY2011 | 12.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 65.9M | +4% | |
| Q1 FY26 | 65.8M | +4% | |
| Q4 FY25 | 64.7M | +3% | |
| Q3 FY25 | 64.2M | +3% | |
| Q2 FY25 | 63.4M | +2% | |
| Q1 FY25 | 63.2M | +2% | |
| Q4 FY24 | 62.7M | +1% | |
| Q3 FY24 | 62.3M | +4% | |
| Q2 FY24 | 62.2M | +4% | |
| Q1 FY24 | 62M | +4% | |
| Q4 FY23 | 61.8M | +4% | |
| Q3 FY23 | 59.7M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Galectin Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.